#Susan e hulse santa monica trial#

Of those randomly assigned, 745 (59%) were in Asia, 512 (40%) in the UK, and 15 (1%) in Africa.

#Susan e hulse santa monica trial#

The RECOVERY trial is registered with ISRCTN (50189673) and ( NCT04381936).īetween May 25, 2021, and May 13, 2022, 1272 patients with COVID-19 and hypoxia receiving no oxygen (eight ) or simple oxygen only (1264 ) were randomly allocated to receive usual care plus higher dose corticosteroids (659 patients) versus usual care alone (613 patients, of whom 87% received low-dose corticosteroids during the follow-up period). Recruitment of patients receiving ventilatory support is ongoing. We report the results for these participants only. On May 11, 2022, the independent data monitoring committee recommended stopping recruitment of patients receiving no oxygen or simple oxygen only due to safety concerns. The primary outcome was 28-day mortality among all randomised participants.

Eligible and consenting adult patients with clinical evidence of hypoxia (ie, receiving oxygen or with oxygen saturation <92% on room air) were randomly allocated (1:1) to either usual care with higher dose corticosteroids (dexamethasone 20 mg once daily for 5 days followed by 10 mg dexamethasone once daily for 5 days or until discharge if sooner) or usual standard of care alone (which included dexamethasone 6 mg once daily for 10 days or until discharge if sooner). This randomised, controlled, open-label platform trial (Randomised Evaluation of COVID-19 Therapy ) is assessing multiple possible treatments in patients hospitalised for COVID-19. We evaluated the use of a higher dose of corticosteroids in this patient group. Low-dose corticosteroids have been shown to reduce mortality for patients with COVID-19 requiring oxygen or ventilatory support (non-invasive mechanical ventilation, invasive mechanical ventilation, or extracorporeal membrane oxygenation).